Next Article in Journal
Analyzing Free-Hand Sound-Tracings of Melodic Phrases
Next Article in Special Issue
Analysis of Xanthine Oxidase Inhibitors from Clerodendranthus spicatus with Xanthine Oxidase Immobilized Silica Coated Fe3O4 Nanoparticles
Previous Article in Journal
Acknowledgement to Reviewers of Applied Sciences and Announcement of the 2017 Outstanding Reviewer Awards Winners
Previous Article in Special Issue
Reduction of T2 Relaxation Rates due to Large Volume Fractions of Magnetic Nanoparticles for All Motional Regimes
Open AccessArticle

Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro

Laboratory for Medical Engineering, Division of Materials Science and Chemical Engineering, Graduate School of Engineering, Yokohama National University, Yokohama Kanagawa 240-8501, Japan
Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka 573-1121, Japan
Department of Biotechnology, Panjab University, Chandigarh 160014, India
Vice Chancellor BBA (Central) University, Lucknow 226027, India
Department of Oncologic Pathology, Graduate School of Medicine, Mie University, Tsu, Mie 514-8507, Japan
Author to whom correspondence should be addressed.
Appl. Sci. 2018, 8(1), 134;
Received: 30 October 2017 / Revised: 23 December 2017 / Accepted: 28 December 2017 / Published: 18 January 2018
(This article belongs to the Special Issue Biological Applications of Magnetic Nanoparticles)
Patients with metastatic castration-resistant prostate cancer (mCRPC) have poor outcomes. Docetaxel (DTX)-based therapy is a current standard treatment for patients with mCRPC. Approaches combining conventional chemotherapeutic agents and nanoparticles (NPs), particularly iron oxide NPs, may overcome the serious side effects and drug resistance, resulting in the establishment of new therapeutic strategies. We previously reported the combined effects of Fe3O4 nanoparticles (Fe3O4 NPs) with DTX on prostate cancer cells in vitro. In this study, we investigated the combined effects of Fe3O4 NPs and rapamycin or carboplatin on prostate cancer cells in vitro. Treatment of DU145 and PC-3 cells with Fe3O4 NPs increased intracellular reactive oxygen species (ROS) levels in a concentration-dependent manner. Treatment of both cell lines with 100 μg/mL Fe3O4 NPs for 72 h resulted in significant inhibition of cell viability with a different inhibitory effect. Combination treatments with 100 µg/mL Fe3O4 NPs and 10 µM carboplatin or 10 nM rapamycin in DU145 and PC-3 cells significantly decreased cell viability. Synergistic effects on apoptosis were observed in PC-3 cells treated with Fe3O4 NPs and rapamycin and in DU145 cells with Fe3O4 NPs and carboplatin. These results suggest the possibility of combination therapy with Fe3O4 NPs and various chemotherapeutic agents as a novel therapeutic strategy for patients with mCRPC. View Full-Text
Keywords: prostate cancer; Fe3O4 nanoparticles; carboplatin; rapamycin; reactive oxygen species prostate cancer; Fe3O4 nanoparticles; carboplatin; rapamycin; reactive oxygen species
Show Figures

Figure 1

MDPI and ACS Style

Kojima, K.; Takahashi, S.; Saito, S.; Endo, Y.; Nittami, T.; Nozaki, T.; Sobti, R.C.; Watanabe, M. Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro. Appl. Sci. 2018, 8, 134.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop